Impact of Whole-Genome Sequencing of *Mycobacterium Tuberculosis* On Treatment Outcomes for MDR-TB/ XDR-TB: A Systematic Review Protocol

Druti Hazra  
Kasturba Medical College Manipal

Connie Lam  
ICPMR: Institute of Clinical Pathology and Medical Research

Vijay Shree Dhyani  
Manipal Academy of Higher Education

Bhumika T V  
Manipal Academy of Higher Education

Kiran Chawla  
Kasturba Medical College Manipal  https://orcid.org/0000-0002-4010-4088

Vitali Sintchenko  
ICPMR: Institute of Clinical Pathology and Medical Research

Protocol

**Keywords:** Tuberculosis, Mycobacterium tuberculosis, drug resistance, treatment outcomes, genomics, whole genome sequencing

**Posted Date:** November 15th, 2021

**DOI:** https://doi.org/10.21203/rs.3.rs-1046897/v1

**License:** This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

The emergence of drug-resistant tuberculosis (DR-TB) is a persistent threat to public health. The detection of DR-TB requires culture-based drug susceptibility testing (DST) or rapid molecular assays for targeted genes. The recent advances in Whole-genome sequencing (WGS) technology have offered a new capacity to identify resistance-conferring mutations in Mycobacterium tuberculosis (MTB). This study reviews and quantifies the emerging evidence on the association between genomic markers of drug resistance in MTB identified by WGS and treatment outcomes for DR-TB.

Methods

A literature search will be conducted in NCBI PubMed, Scopus, Cochrane Library, Web of Science, and CINAHL (Ebsco) to retrieve all the relevant original reports from 2000 onwards. Clinical trials and observational studies describing different applications of WGS to genotypic resistance testing for TB and detection of MDR-TB/ XDR-TB as well as treatment outcomes of the patients will be included. Two primary reviewers will separately screen and select papers for data extraction, risk of bias, and assess the quality. Any disagreement between the reviewers’ will be clarified by a third reviewer. The $I^2$ statistics will be used to assess the heterogeneity of the included studies and if the data are sufficiently homogenous, a meta-analysis will be performed. The Egger's test and visual representation of the funnel plot will be used to monitor for publication bias. Narrative data synthesis will be conducted for all the included studies if performing meta-analysis is not possible.

Discussion

This systematic review will examine the evidence on the feasibility and added value of WGS in improving treatment outcomes in DR-TB patients. The rapid detection of drug-resistance conferring mutations and selection of appropriate drug regimens is likely to improve the cure rates while minimizing adverse events and treatment costs. Hence, the outcome of this systematic review will inform policy-making and will guide clinical laboratory practice to improve drug resistance diagnostic capacity and treatment outcomes.

Systematic review registration:

PROSPERO CRD42020197099.

Introduction
Despite the global efforts, drug-resistant tuberculosis (DR-TB) remains a major obstacle in tuberculosis (TB) eradication programs. Globally in 2019, the World Health Organization (WHO) reported around 465,000 new cases and approximately 182,000 deaths due to multi-drug resistant TB (MDR-TB)/rifampicin-resistant TB (RR-TB) [1]. As per WHO, 17.7% of prior treated cases and 3.3% of new patients had RR/MDR-TB, and successful treatment outcomes were accounted for only 57% of cases with RR/MDR-TB [1]. *Mycobacterium tuberculosis* (MTB) isolates resistant to first-line drugs isoniazid and rifampicin are defined as MDR-TB, and extensively drug-resistant TB (XDR-TB) are referred to as MDR isolates, along with resistance to a fluoroquinolone and another Group A drug (e.g., linezolid or bedaquiline) [2–4]. The detection of DR-TB using culture-based drug susceptibility testing (DST) can be challenging. It remains time-consuming, expensive, and requires a high-capacity laboratory, as well as methodological standardization of testing for second-line antimycobacterial agents [5, 6]. In 2019, only 71% of RR/MDR-TB cases were tested for second-line drug fluoroquinolones, which could be due to inaccessibility of test facilities or culture of slow-growing MTB for phenotypic DST [1].

Currently available genotypic assays can rapidly provide common drug resistance which is advantageous over time-consuming phenotypic DST; however, these diagnostic methods can only detect specific genetic mutations already known to confer drug resistance [7, 8]. Whole-genome sequencing (WGS) has become a reliable tool to overcome the limitations of probe-based diagnosis methods and provide a better insight into emerging clinically relevant mutations in the MTB genome [9, 10]. WGS is relatively rapid and has the capacity to identify a broad range of genetic polymorphisms, which can guide us to new treatment strategies and improve case management for DR-TB [8, 11]. The WGS-based applications are expanding to TB diagnostics and recent studies demonstrated the applicability of WGS in the clinical management of tuberculosis [10, 12, 13]. Also, previous systematic reviews of Mycobacteriology have emphasized the application of WGS from a different perspective. The use of WGS for TB transmission and outbreak investigations was reviewed by Hatherell HA [14] and Van Der Werf MJ et.al. [15], whereas, Papaventsis D et.al [8] and Nieto Ramirez LM et.al. [16] addressed the diagnostic accuracy of WGS for detecting the mutations conferring drug resistance. This systematic review will bridge the knowledge gaps on the efficacy of MTB whole-genome sequencing on patients' treatment outcomes.

The standardized treatment approach for individual MDR-TB cases does not always lead to successful treatment outcomes. As several patients with a history of TB treatment develop MDR/XDR TB, baseline drug resistance has been recognized as a major factor that impacts the treatment efficacy [17]. Therefore, in this present review, we aimed to assess the applicability of WGS to detect genomic markers of drug resistance in *M. tuberculosis* and explore their association with treatment outcomes.

**Objectives:**

To evaluate the efficacy of whole-genome sequencing as a predictor of treatment outcomes for multidrug-resistant/extensively drug-resistance tuberculosis compared to phenotypic drug-susceptibility testing.
Methods

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) statements were used to develop this systematic review protocol [18] (Additional file 1). This present protocol was registered with the International Prospective Register of Systematic Reviews (PROSPERO) database (registration ID: CRD42020197099).

Eligibility criteria

We will include non-Randomized clinical trials (NRCT), Randomized clinical trials (RCT), and observational studies, such as case-control, cohort, case series describing different applications of WGS to genotypic resistance testing for TB and detection of MDR-TB/XDR-TB as well as treatment outcomes of the patients. The exclusion and inclusion criteria of this study are defined using PICOS (Population, Intervention, Comparator, Outcome, Study design) framework [19] (Table 1).

Table 1
Inclusion and exclusion criteria.

| PICOS criteria | Inclusion | Exclusion |
|----------------|-----------|-----------|
| Population     | Studies conducted on MDR-TB/XDR-TB groups | Studies reported any single drug resistance TB group e.g. RR-TB group |
| Intervention   | Whole-genome sequencing | Targeted genome sequencing |
| Comparator     | Phenotypic DST | |
| Outcome        | Studies reported MDR-TB/XDR-TB treatment outcomes | |
| Study design   | Original researches: clinical-trials and observational studies like case-control, cohort, case series | Conference abstracts, reviews, letters to editors, editorials |

Search strategy

Five electronic databases will be used to conduct a literature search i.e. Scopus, Cochrane Library, Web of Science, NCBI PubMed (MEDLINE), and CINAHL (Ebsco). The structured search strategy will be employed based on the keywords related to “drug resistance tuberculosis”, ‘tuberculosis’, “treatment outcome” and “whole genome sequencing”. Also, the site-specific biomedical terms like Medical Subject Headings (MeSH), Emtree will be included and the Boolean operators will be used to combine all of the search terms [20] (Additional file 2). The search data will be reviewed and validated by a specialist health science librarian. The results will be limited to the English language and original research articles from the year 2000 onwards will be included. Letters to the editor, review articles and comments will not be included in this study. There will not be any geographical filter as the review intends to include global data.
Selection of studies

The search results retrieved from the electronic databases will be imported in Zotero and duplicate studies will be removed. For the title-abstract screening phase, the retrieved studies will be exported to a Microsoft Excel spreadsheet (Microsoft, 2019). Two reviewers will independently assess the abstracts using eligibility criteria. Studies identified as relevant by at least one of the reviewers will be included for full-text assessment. The full text will be retrieved and assessed by two reviewers independently. Any disagreement between reviewers’ interpretation will be initially discussed between them, and, if not resolved, will be clarified by a third reviewer. The final decision of including/excluding a study will be confirmed by all reviewers and appropriately documented in the PRISMA flow chart [21].

Data extraction: Pertinent data will be extracted separately by the primary reviewers from each included article. A standardized data extraction spreadsheet will be developed by the reviewers after a pilot assessment. The key details to be extracted will include the following: Basic details (i.e. names of authors, year of publication, journal, the country where patients were enrolled in the study, duration of the study, study design, study setting, method of WGS employed in the study), study participants (number of patients included, age, gender, risk groups when available), main findings (MTB isolates subjected to phenotypic DST and WGS, MDR-TB/XDR-TB numbers, mutations detected by WGS, technical details about diagnostic tools, MTB genetic lineages), treatment outcomes (treatment completed, cured, died, defaulted, TB relapse).

Risk of bias and quality assessment

The quality assessment of included studies will be performed using the Cochrane Risk of Bias 2 (RoB 2) tool for RCT [22], Cochrane Risk of Bias in Non-randomised Studies of Interventions (ROBINS-I) tool for NRCT [23] Newcastle-Ottawa Scale (NOS) for quasi-experimental and observational studies [24] or based on the study designs. Two reviewers individually will determine the risk of bias and based on the study design, studies will be classified as having a ‘low,’ ‘high,’ or ‘unclear’ risk of bias. A third reviewer will address any discrepancies between the primary reviewers.

Data synthesis and analysis

The study characteristics and outcome data will be collated into tables and summarised narratively. The I² statistics will be used to assess the heterogeneity of the included studies and if the data are sufficiently homogenous, a meta-analysis will be performed. Random or fixed-effect meta-analysis will be carried out to estimate the individual study effect and produce a pooled estimate summarizing data on the predictors of all distinct treatment outcomes [25, 26]. Standardized mean differences will be used to assess continuous outcomes and odds ratio (OR) and Risk ratio (RR) will be used to estimate the effect sizes of categorical outcomes, with a 95% confidence interval (CI) [27]. The degree of heterogeneity among the studies will be represented visually using a forest plot [28] and the value of the I² statistics and the Egger’s test and visual representation of the funnel plot will be used to assess publication bias [29, 30]. Narrative data synthesis will be conducted for all the included studies if performing meta-
analysis is not possible. We will adhere to the Grading of Recommendations Assessment, Development, 
and Evaluation (GRADE) approach to assess the data quality presented in the systematic review [31, 32]. 
Reporting of the systematic review and meta-analysis-PRISMA 2020 guidelines will be used to report this 
systematic review [21].

Subgroup analysis

A subgroup analysis will be conducted, in cases of a significant heterogenicity observed in pooled 
estimates, considering the following grouping characteristics [27, 33]

i. Type of drug-resistant strains of MTB: MDR-TB, XDR-TB.

ii. Participants demographic and risk factors: age, HIV status.

iii. Study characteristics: geographical area and study design.

iv. Types of sequencing platforms and data analysis tools.

v. Participants’ treatment outcomes: treatment completed, cured, died, defaulted, TB relapse.

Discussion

Despite recent advances in the application of WGS to the prediction of drug resistance in MTB, the 
association between detection of resistance or susceptibility from genome sequence data and the 
treatment outcomes in the case of DR-TB/ MDR-TB/ XDR-TB remains untested. This systematic review 
will interrogate the existing data on the feasibility and added value of WGS in improving treatment 
outcomes in TB patients. The rapid detection of drug-resistance conferring mutations and selection of 
appropriate drug regimens is likely to improve the cure rates while minimizing adverse events and 
treatment costs for TB patients. Hence, the outcome of this systematic review will be beneficial for policy-
making and will guide clinical laboratory practice to improve drug resistance diagnostic capacity and 
treatment outcomes. While the genomic sequencing methods and bioinformatics analyses employed in 
studies included in this systematic review will not be specifically scrutinised, we acknowledge the 
importance of wet and dry laboratory techniques and analytic pipelines in the implementation of WGS-
guided selection of therapy for DR-TB [34]. We will pay particular attention to the interpretation of drug-
resistance mutations, their impact on phenotypic DST results, and the ranking of their significance and 
will recommend a minimum data required for a standardised assessment of genetic mutation-clinical 
outcome associations in order to avoid biases. In addition, this review will shed light on important 
challenges in the translation of genomic research into TB control and personalised therapeutic 
interventions and identify relevant research gaps for further studies.

List Of Abbreviations
Declarations

Ethics approval and consent to participate: Not applicable

Consent for publication: Not applicable.

Availability of data and materials: Not applicable

Competing interests: The authors declare that they have no competing interests.

Funding: None

Authors’ contributions:

The study was conceptualized by VS, KC, DH, CL and supervised by KC, VS, VSD, and BTV. The search strategy was designed by DH, VSD, and CL, and the literature review was performed by DH and CL. The manuscript has been written by DH and reviewed and improved by VS, KC, VSD, CL, and BTV. All authors critically revised the current protocol and approved the final version of this manuscript.

Acknowledgments: Not applicable

References

1. World Health Organization. Global Tuberculosis Report 2020. World Health Organization. 2020. https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf

2. Nellums LB, Rustage K, Hargreaves S, Friedland JS. Multidrug-resistant tuberculosis treatment adherence in migrants: a systematic review and meta-analysis. BMC Med. 2018;16:27. doi: 10.1186/s12916-017-1001-7.

3. World Health Organization. Global Tuberculosis Report 2016. World Health Organization. 2016. http://apps.who.int/iris/bitstream/10665/250441/1/9789241565394-eng.pdf?ua=1.

4. World Health Organization. WHO announces updated definitions of extensively drug-resistant tuberculosis. World Health Organization. 2021. https://www.who.int/news/item/27-01-2021-who-announces-updated-definitions-of-extensively-drug-resistant-tuberculosis.

5. Horne DJ, Pinto LM, Arentz M, Lin SY, Desmond E, Flores LL, et al. Diagnostic accuracy and reproducibility of WHO-endorsed phenotypic drug susceptibility testing methods for first-line and second-line antituberculosis drugs. J Clin Microbiol. 2013;51:393–401. doi: 10.1128/JCM.02724-12.
6. Ruesen C, Riza AL, Florescu A, Chaidir L, Editoiu C, Aalders N, et.al. Linking minimum inhibitory concentrations to whole genome sequence-predicted drug resistance in Mycobacterium tuberculosis strains from Romania. Sci Rep. 2018;8: 9676. doi: 10.1038/s41598-018-27962-5.

7. Chen ML, Doddi A, Royer J, Freschi L, Schito M, Ezewudo M, et.al. Beyond multidrug resistance: Leveraging rare variants with machine and statistical learning models in Mycobacterium tuberculosis resistance prediction. EBioMedicine. 2019;43:356–369. doi: 10.1016/j.ebiom.2019.04.016.

8. Papaventsis D, Casali N, Kontsevaya I, Drobniewski F, Cirillo DM, Nikolayevsky V. Whole genome sequencing of Mycobacterium tuberculosis for detection of drug resistance: a systematic review. Clin Microbiol Infect. 2017;23:61–68. doi: 10.1016/j.cmi.2016.09.008.

9. Katale BZ, Mbelele PM, Lema NA, Campino S, Mshana SE, Rweyemamu MM, et.al. Whole genome sequencing of Mycobacterium tuberculosis isolates and clinical outcomes of patients treated for multidrug-resistant tuberculosis in Tanzania. BMC Genomics. 2020;21:174. doi: 10.1186/s12864-020-6577-1.

10. Witney AA, Gould KA, Arnold A, Coleman D, Delgado R, Dhillon J, et.al. Clinical application of whole-genome sequencing to inform treatment for multidrug-resistant tuberculosis cases. J Clin Microbiol. 2015;53:1473–83. doi: 10.1128/JCM.02993-14.

11. Walker TM, Kohl TA, Omar SV, Hedge J, Elias CD, Bradley P, et.al. Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study. Lancet Infect Dis. 2015;15:1193–1202. doi: 10.1016/S1473-3099(15)00062-6.

12. Meehan CJ, Goig GA, Kohl TA, Verboven L, Dippenaar A, Ezewudo M, et.al. Whole genome sequencing of Mycobacterium tuberculosis: current standards and open issues. Nat Rev Microbiol. 2019;17:533–545. doi: 10.1038/s41579-019-0214-5.

13. Witney AA, Cosgrove CA, Arnold A, Hinds J, Stoker NG, Butcher PD. Clinical use of whole genome sequencing for Mycobacterium tuberculosis. BMC Med. 2016;14:46. doi:10.1186/s12916-016-0598-2.

14. Hatherell HA, Colijn C, Stagg HR, Jackson C, Winter JR, Abubakar I. Interpreting whole genome sequencing for investigating tuberculosis transmission: a systematic review. BMC Med. 2016;14:21. doi: 10.1186/s12916-016-0566-x.

15. Van Der Werf MJ, Ködmön C. Whole-genome sequencing as tool for investigating international tuberculosis outbreaks: a systematic review. Front Public Health. 2019; 7:87. doi: 10.3389/fpubh.2019.00087.

16. Nieto Ramirez LM, Quintero Vargas K, Diaz G. Whole genome sequencing for the analysis of drug resistant strains of Mycobacterium tuberculosis: a systematic review for bedaquiline and delamanid. Antibiotics. 2020;9:133. doi: 10.3390/antibiotics9030133.

17. He G, Li Y, Chen X, Chen J, Zhang W. Prediction of treatment outcomes for multidrug-resistant tuberculosis by whole-genome sequencing. Int J Infect Dis. 2020;96:68–72. doi: 10.1016/j.ijid.2020.04.043.
18. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;350:g7647. doi: 10.1136/bmj.g7647.

19. McKenzie JE, Brennan SE, Ryan RE, Thomson HJ, Johnston RV, Thomas J. Defining the criteria for including studies and how they will be grouped for the synthesis. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions. 2nd ed. Chichester: Wiley; 2019. p. 33–65. doi:10.1002/9781119536604.ch3

20. Lefebvre C, Glanville J, Briscoe S, Littlewood A, Marshall C, Metzendorf MI, et.al. Searching for and selecting studies. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions. 2nd ed. Chichester: Wiley; 2019. p.67–107. doi:10.1002/9781119536604.ch4.

21. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10, 89. doi:10.1186/s13643-021-01626-4

22. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi:10.1136/bmj.l4898.

23. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. doi:10.1136/bmj.i4919.

24. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–5. doi: 10.1007/s10654-010-9491-z.

25. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88. doi: 10.1016/0197-2456(86)90046-2.

26. Rice K, Higgins JPT, Lumley T. A re-evaluation of fixed effect(s) meta-analysis. J R Stat Soc Ser A Stat Soc. 2018;181,205–227. doi: 10.1111/rssa.12275.

27. Deeks JJ, Higgins JP, Altman DG, Cochrane Statistical Methods Group. Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions. 2nd ed. Chichester: Wiley; 2019. p.241–84. https://doi.org/10.1002/9781119536604.ch10

28. Lewis S, Clarke M. Forest plots: trying to see the wood and the trees. BMJ. 2001;322:1479–80. doi: 10.1136/bmj.322.7300.1479.

29. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34. doi: 10.1136/bmj.315.7109.629

30. Duval S, Tweedie R. Trim and fill: a simple funnel-plot–based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455–63. doi: 10.1111/j.0006-341x.2000.00455.x.
31. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–6. doi: 10.1136/bmj.39489.470347.

32. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et.al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383–94. doi: 10.1016/j.jclinepi.2010.04.026.

33. Richardson M, Garner P, Donegan S. Interpretation of subgroup analyses in systematic reviews: a tutorial. Clin Epidemiol Glob Health. 2019;7:192–198. doi: 10.1016/j.cegh.2018.05.005.

34. World Health Organization. The use of next-generation sequencing technologies for the detection of mutations associated with drug resistance in Mycobacterium tuberculosis complex: technical guide. World Health Organization. 2018. https://www.who.int/publications/i/item/WHO-CDS-TB-2018.19

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- AdditionalFile1.docx
- AdditionalFile2.docx